Dataset of pharmacotherapy in autism spectrum disorder
Year: 2025
Type: data-paper
Study design: Observational Study
Abstract: Pharmacological interventions are widely used in autism spectrum disorder (ASD). We investigated the profile of psychopharmaceutical in a sample of children with ASD of low socioeconomic stratum enrolled and the public school in the city of Embu das Artes, Sao Paulo Brazil. From 149 children with a diagnosis of ASD identified in the municipal education department, informant consents were obtained from 129 children's parents. Data collection was performed through clinical evaluation of the children and face to face application of a questionnaire for parents regarding medication use. The participants socioeconomic stratum was mostly C (72.86 %), followed by B (16,27 %), D (10.07 %), and A (0.7 %) who do not undergo specialized multi-professional educational and behavioral intervention. Among the participants 57.36 % were under psychopharmacological intervention and 33.78 % were under a polypharmacy regimen. Typical antipsychotics were used for 35.4 % followed by atypical antipsychotics (27.43 %), antiseizure (19.47 %), and tricyclic antidepressants (7.08 %). The association of risperidone with valproic acid prevailed in 17.68 % of the sample. ASD levels 2 and 3, epilepsy and age were associated with a higher rate of psychopharmaceutical use. The present dataset can be used to investigate the rational use of medication in the ASD population to monitor potential adverse effects, and to compare with the ASD population across the world
Source: Data in Brief
Authors: Sebastião Gonçalves de Barros Neto, Catherine Oliveira de Araújo, Renandro de Carvaho Reis, Kelson James da Silva Almeida, Decio Brunoni, Roberta Monterazzo Cysneiros
Language: English
Subfield: Cognitive Neuroscience
Field: Neuroscience
Domain: Life Sciences
Open Access status: gold
Estimated APC paid: $1,220
OpenAlex ID: W4411399346